Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OB756 vs hydroxyurea in intermediate- or high-risk myelofibrosis (Phase II/III, randomized double-blind)
ChiCTR2600122323Phase 3Completed
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bewintinib in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and myelofibrosis (MF) (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Spleen volume reduction ≥35% at 24 weeks (IRC evaluation). Started Apr 2026; status: completed.
02
Drugs
bewintinib
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)myelofibrosis (MF)
Beyond the preview
Go deeper on ChiCTR2600122323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122323.